このエントリーをはてなブックマークに追加
ID 69959
FullText URL
Author
Ahn, Myung-Ju Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine
Cho, Byoung Chul Medical Oncology Department-501, ABMRC, Yonsei University
Ohashi, Kadoaki Department of Respiratory Medicine, Okayama University Hospital ORCID Kaken ID researchmap
Izumi, Hiroki Thoracic Oncology, National Cancer Center Hospital East
Lee, Jong-Seok Hematology/Oncology, Seoul National University Bundang Hospital
Han, Ji-Youn Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy
Chiang, Chi-Lu Department of Chest Medicine, Taipei Veterans General Hospital
Huang, Shuang Amgen Inc.
Hamidi, Ali Amgen Inc.
Mukherjee, Sujoy Amgen Inc.
Xu, Krista Lin Amgen Asia Pacific Pte. Ltd.
Akamatsu, Hiraoki Internal Medicine III, Wakayama Medical University
Abstract
Introduction: Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.
Methods: Patients with previously treated, advanced SCLC received 10 mg tarlatamab every 2 weeks. The primary endpoint was objective response rate (ORR) by blinded independent central review (RECIST version 1.1). Key secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. The present analysis includes patients enrolled at sites in Asia.
Results: A total of 43 patients were enrolled at sites in Asia. ORR was 46.3% (95% confidence interval [CI], 30.7–62.6) and median DOR was 7.2 months (95% CI 3.9 to not estimable). The median follow-up was 16.6 months for PFS and 21.2 months for OS. Median PFS was 5.4 months (95% CI 3.0–8.1) and median OS was 19.0 months (95% CI 11.4 to not estimable). The most common treatment-emergent adverse event (AE) was cytokine release syndrome (48.8%), and all such events were grade 1 or 2. There were no discontinuations due to treatment-related AEs.
Conclusions: Tarlatamab demonstrated durable responses and promising survival outcomes with a manageable safety profile in this post hoc analysis of patients from Asia with previously treated SCLC.
Trial Registration: ClinicalTrials.gov, NCT05060016.
Keywords
Small cell lung cancer (SCLC)
Tarlatamab
DLL3
Bispecific T-cell engager
Asian patients
Published Date
2025-09-04
Publication Title
Oncology and Therapy
Volume
volume13
Issue
issue4
Publisher
Springer Science and Business Media LLC
Start Page
1041
End Page
1054
ISSN
2366-1070
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© The Author(s) 2025
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1007/s40487-025-00372-0
License
http://creativecommons.org/licenses/by-nc/4.0/
Citation
Ahn, MJ., Cho, B.C., Ohashi, K. et al. Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer. Oncol Ther 13, 1041–1054 (2025). https://doi.org/10.1007/s40487-025-00372-0
助成情報
( Amgen Inc. )